[ad_1]
Radnor, Pennsylvania, May 16, 2021 /PRNewswire/-Kessler Topaz Meltzer & Check, LLP Law Firm Announces that Securities Fraud Class Action Lawsuit Has Been Filed United States North District District Court California Representation of persons purchasing or acquiring FibroGen securities and/or selling put options against FibroGen, Inc. (NASDAQ: FGEN) (“FibroGen”) From October 18, 2017 by April 6, 2021(Inclusive) (“During Class”).
Investor deadline reminder: Investors who purchase or acquire FibroGen securities And/or put options sold During class, Not later than June 11, 2021, Seeking to be appointed as the chief plaintiff representative of this category. For additional information or to learn how to participate in this lawsuit, please contact Kessler Topaz Meltzer & Check, LLP: James Marlow (Esq.) (484) 270-1453 or Adrienne Bell, Esq. (484) 270-1435; Toll free (844) 887-9500; Send by email to info@ktmc.com; or Click on https://www.ktmc.com/fibrogen-class-action-lawsuit?utm_source=PR&utm_medium=Link&utm_campaign=fibrogen
FibroGen is a biopharmaceutical company dedicated to the development of drugs for the treatment of anemia, fibrotic diseases and cancer. Its most advanced product is roxadustat (“Roxa”), which is an oral small molecule inhibitor of hypoxia-inducible factor-prolyl hydroxylase activity, which works by stimulating the body’s natural pathway to produce red blood cells.
Class time starts at October 18, 2017 When FibroGen announced that the China Food and Drug Administration (“CFDA”) had accepted Roxa’s New Drug Application (“NDA”), the drug was based on two Phase 3 studies conducted in 2006 China, “A study on CKD [chronic kidney disease] Compare roxadustat to the brand’s epoetin alfa[] A non-dialysis study of CKD compared roxadustat with placebo. “Both studies” reached their primary efficacy endpoints, and no new or unexpected safety signals were found. “FibroGen praised the positive safety of these studies throughout the study period.
After overcoming the obstacles to prove to the CFDA that Roxa is safe enough to submit an NDA, FibroGen began to demonstrate that it is ready to conduct a Phase 3 trial that is sufficient to support the NDA to support the US Food and Drug Administration (“FDA”). In 2019, FibroGen submitted an NDA application to the FDA to approve Roxa for the treatment of anemia caused by CKD.
The truth begins to surface March 1, 2021 When the market was closed, FibroGen announced that the FDA planned to hold an advisory committee meeting one year after the initial submission of Roxa’s NDA to review Roxa’s NDA. The advisory committee meeting held late in the review process indicated that the application was problematic, and at best the FDA’s approval decision could be delayed, and the worst sign was that the FDA might not approve the drug.Following this news, FibroGen’s share price fell $ 12.46 Per share or 25%.
Then continue April 6, 2021After the market closed, FibroGen issued a press release showing that FibroGen’s previously disclosed safety data included post-mortem changes to stratification factors, but not analysis based on pre-specified stratification factors. Due to these changes, the complaint stated that FibroGen was forced to admit that, compared with the previously approved Roxa, Roxa did not reduce the risk of cardiovascular events or hospitalization, and based on the current situation, the approved anemia injection was used as a control. The specified stratification factor.Following this news, FibroGen’s stock price fell $14.90Or 43%, closed at $19.74 Per share April 7, 2021.
The complaint stated that during the entire class, the defendant made false and/or misleading statements or failed to disclose the following: (1) Based on the safety data of two phase three trials conducted by FibroGen in 2006. China, Any safety data obtained from the global Phase 3 trial needs to be changed afterwards to the stratification factor to meet the FDA requirements; (2) FibroGen from Roxa’s global Phase 3 global plan for CKD anemia treatment The disclosure of cardiovascular safety analysis includes the post-event changes of stratification factors; (3) FibroGen uses pre-specified stratification factors to analyze and obtain a higher hazard ratio (point estimate of relative risk) and 95% confidence Interval; (4) According to these analyses, FibroGen cannot conclude that compared with Epoetin-α, Roxa reduces the risk of MACE+ in dialysis (or better than MACE+), and the difference between MACE and MACE+ in event dialysis Risk reduction (or better than the latter); (5) As a result, FibroGen faces great uncertainty, that is, its NDA for Roxa as a treatment for CKD anemia will be approved by the FDA; (6) Due to the above reasons, The defendant’s statements regarding FirboGen’s business, operations and prospects were false and misleading and/or unreasonable statements at all relevant times.
FibroGen Investors may Not later than June 11, 2021, Seeking to be appointed as the chief plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other consultants, or may choose not to do anything and remain absent. The lead plaintiff is the representative of the class members who represent all litigations in the litigation. In order to be appointed as the main plaintiff, the court must determine that the claims of the class member are typical of the claims of other class members, and that the class member will fully represent the class. Your ability to share any recovery is not affected by the decision whether or not to act as the main plaintiff.
Attorney Kessler Topaz Meltzer & Check is suing class actions involving securities fraud, breach of fiduciary duty, and other violations of state and federal laws in state and federal courts across the country. Kessler Topaz Meltzer & Check, LLP is the driving force of corporate governance reform, has represented institutional and individual investors from United States And all over the world. The company represents investors, consumers and whistleblowers (private citizens who report fraud against the government and share the recovery of government funds). Kessler Topaz Meltzer & Check, LLP did not file a lawsuit.For more information about Kessler Topaz Meltzer & Check, LLP, please visit www.ktmc.com.
contact:
Kessler Topaz Meltzer & Check, LLP
James Maro, Jr.
Adrienne Bell, Esq.
280 Prussian Road
Radnor, Pennsylvania 19087
(844) 887-9500 (toll free)
info@ktmc.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/fgen-alert–kessler-topaz-meltzer–check-llp-reminds-investors-of-securities-fraud-class-action-lawsuit-filed-against- fibrogen-inc — expanded-class-period-301292033.html
Source: Kessler Topaz Meltzer & Check, LLP
[ad_2]
Source link
